Literature DB >> 6327028

Enzymatic activation and binding of adriamycin to nuclear DNA.

B K Sinha, M A Trush, K A Kennedy, E G Mimnaugh.   

Abstract

Rat liver microsomal activation of the anthracycline antitumor drug, Adriamycin, in the presence of reduced pyridine nucleotide under anaerobic conditions produces reactive species that bind covalently to cellular macromolecules including DNA. Since the nuclear membrane contains enzymes capable of activating Adriamycin, we have examined activation of Adriamycin by isolated nuclei. The anaerobic incubation of Adriamycin with rat hepatic nuclei resulted in the formation of the Adriamycin semiquinone free radical. Moreover, this activation resulted in the covalent binding of Adriamycin to nuclear DNA. The binding of Adriamycin to DNA was reduced pyridine nucleotide and time dependent and was significantly decreased in the presence of reduced glutathione or ethylxanthate . Dicumerol , an inhibitor of DT-diaphorase, in contrast, had no effect on this binding. When the incubation was carried out in the presence of oxygen, no semiquinone radical was detected; however, superoxide and hydroxyl radicals were readily detected by a spin-trapping technique. Furthermore, little binding of Adriamycin to nuclear DNA was observed under aerobic conditions. These observations suggest that the nuclear activation and covalent binding of Adriamycin to DNA may be important in the biochemical actions of this drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327028

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Stability of adriamycin-induced DNA adducts and interstrand crosslinks.

Authors:  A van Rosmalen; C Cullinane; S M Cutts; D R Phillips
Journal:  Nucleic Acids Res       Date:  1995-01-11       Impact factor: 16.971

Review 2.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

3.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

4.  Formation of adriamycin--DNA adducts in vitro.

Authors:  C Cullinane; S M Cutts; A van Rosmalen; D R Phillips
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

5.  Covalent modification of DNA by daunorubicin.

Authors:  M Purewal; J G Liehr
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  Nitrolipids in kidney physiology and disease.

Authors:  Soma Jobbagy; Roderick J Tan
Journal:  Nitric Oxide       Date:  2018-03-29       Impact factor: 4.427

7.  Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicin.

Authors:  M C Mormont; R von Roemeling; R B Sothern; J S Berestka; T R Langevin; M Wick; W J Hrushesky
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

8.  Nicotine decreases the cytotoxicity of doxorubicin towards MCF-7 and KB-3.1 human cancer cells in culture.

Authors:  Yanfei Zhou; Xinbin Gu; Ebrahim Ashayeri; Renshu Zhang; Rajagopalan Sridhar
Journal:  J Natl Med Assoc       Date:  2007-04       Impact factor: 1.798

9.  Characterization of covalent adriamycin-DNA adducts.

Authors:  S M Zeman; D R Phillips; D M Crothers
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

10.  Formation of DNA-adducts and induction of DNA-crosslinks and chromosomal aberrations by the new potent anthracycline antitumor antibiotics: morpholinodaunomycin, cyanomorpholinodaunomycin and cyanomorpholinoadriamycin.

Authors:  J Westendorf; G Groth; G Steinheider; H Marquardt
Journal:  Cell Biol Toxicol       Date:  1985-01       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.